Latest Breaking News On - Nohla therapeutics - Page 1 : comparemela.com
Seattle biotech startup Deverra Therapeutics raising cash to develop cellular immunotherapies
geekwire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from geekwire.com Daily Mail and Mail on Sunday newspapers.
Marinus Pharma (MRNS) Appoints Sarah Noonberg to its Board
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Posted on 524
Shasqi, a clinical-stage biotechnology company developing precision activated oncology therapeutics with its proprietary Click Activated Protodrugs Against Cancer (CAPAC
TM) platform, announced today the members of its strategic advisory board, which bring a range of expertise to the company including corporate strategy, clinical development, cellular biology, and cancer therapeutics.
“Shasqi has made important progress during the last year with the initiation of our phase 1 clinical trial of SQ3370 and the advancement of our CAPAC drug development platform we’re preparing for the next phase of our growth,” said José M. Mejía Oneto, M.D., Ph.D., Founder and CEO of Shasqi. “We’ve deliberately selected and cultivated a team of strategic advisors with the skills, expertise and experience to help us navigate through the opportunities ahead of us and, ultimately, position us to benefit as many peop
ResearchAndMarkets.com’s offering.
From the early 1900s through the mid-2000s, the global cord blood banking industry proliferated with cord blood banks emerging in all major healthcare markets worldwide. From 2005 to 2010, the market reached saturation and stabilized. From 2010 to 2020, the market began to aggressively consolidate, creating both threats and opportunities within the industry.
Serious threats to the industry include low rates of utilization for stored cord blood, expensive cord blood transplantation procedures, difficulty educating obstetricians about cellular therapies, and an increasing trend toward industry consolidation. Opportunities for the industry include price efficiencies associated with scale and consolidation, accelerated regulatory pathways for cord blood and tissue-based cell therapies, and progress with
vimarsana © 2020. All Rights Reserved.